Centerpoint Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Centerpoint Advisors’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-8,500	Closed	-$29K	–	279
2018 Q3	$29K	Hold	8,500	–	–	0.02%	118
2018 Q2	$32K	Hold	8,500	–	–	0.03%	118
2018 Q1	$35K	Hold	8,500	–	–	0.03%	109
2017 Q4	$40K	Buy	+8,500	New	+$46.8K	0.04%	86

Centerpoint Advisors's KERX Position: Q4 2018 in Review

Centerpoint Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 8,500 shares — an estimated $29K sold.

Centerpoint Advisors first reported a position in KERX in Q4 2017 and held it in 4 quarters. The position peaked at $40K in Q4 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

Centerpoint Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Centerpoint Advisors sold 8,500 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $29K.
Centerpoint Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q4 2017 and held it in 4 quarters.
Centerpoint Advisors's Keryx Biopharmaceuticals Inc position peaked at $40K in Q4 2017.
1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Centerpoint Advisors's 13F filing for Q4 2018, filed 5 Feb 2019.